Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined application of PLR, HPR, and CEA may improve the diagnostic efficacy of distinguishing between colon cancer and benign colon tumors.
|
31809747 |
2020 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recently, a large-scale study on colon cancer revealed that "preoperatively elevated and postoperatively normalized CEA levels" is not an indicator of poor prognosis.
|
31799750 |
2020 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Enhancement of chemosensitivity in 5-fluorouracil-resistant colon cancer cells with carcinoembryonic antigen-specific RNA aptamer.
|
31028570 |
2019 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CEA level and Poorly differentiated histology of colon cancer was significantly correlated with high NLR (P = 0.005 and P = 0.048, respectively).
|
30941323 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, serum levels of GSN were significantly lower in colon cancer patients than those in healthy volunteers, and ROC curves showed serum level of GSN had a better diagnostic value for colon cancer (AUC=0.932) than the traditional tumor biomarker Carcinoembryonic Antigen (CEA) or Carbohydrate Antigen 19-9 (CA199).
|
30854138 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
A multivariate analysis showed that age (odds ratio [OR] 0.97, P < 0.001), tumor size (OR 1.01, P < 0.001), moderate (OR 1.77, P = 0.001) or poorly differentiated/undifferentiated tumor (OR 5.60, P < 0.001), right colon cancer (OR 1.39, P = 0.008), and a positive carcinoembryonic antigen level (OR 1.51, P = 0.004) were independent predictive factors for LNM.
|
31021492 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
This large population-based and propensity score-matched study with long follow-up time provides the first evidence that stage T1N0M0 colon cancer with the elevation of preoperative serum CEA would be a surrogate of aggressive tumor biology and predict poor prognosis.
|
31016378 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secondly, ENST00000455974 showed a better sensitivity and specificity than CEA and CA19-9 in the diagnosis of pMMR CC by drawing the receiver operating characteristic (ROC) curve.
|
30473216 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a transgenic mouse model constitutively expressing human CEA in a spatiotemporal manner as a self-protein and a syngeneic mouse colon cancer cell line, MC38-CEA, overexpressing CEA, we tested the potential of a novel genetic immunotherapy approach against CEA-expressing tumors, using recombinant adeno-associated virus vector encoding CEA (rAAV-CEA) and appropriately timed immune adjuvant application.
|
30666318 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carcinoembryonic antigen (CEA), a routinely used marker for colon cancer, was used as a test glycoprotein.
|
31581071 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth.
|
31192764 |
2019 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Carcinoembryonic antigen (CEA) is a tumor marker for detecting recurrences of adenocarcinomas such as colon cancer.
|
29997989 |
2018 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The prognostic factors of SAR were age (stage II CC and stage III RC), female gender (stage III RC), high CEA level (stage II RC), histological type (stage III CRC), nodal status (stage III CC), recurrence within 1 year (stage III RC), M1b recurrence (stage II CRC), local recurrence (stage II CC), and no surgical resection after recurrence (stage II and III CRC).
|
29876002 |
2018 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using the National Cancer Database (2004-2014), we identified 45,449 individuals with stage I and II colon cancer who did not receive adjuvant chemotherapy and had preoperative CEA levels available.
|
29502035 |
2018 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Analysis of CXCL17 messenger RNA is particularly useful to detect less differentiated colon cancer tumors expressing relatively low carcinoembryonic antigen messenger RNA levels.
|
30198422 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ROC curve analysis showed that serum TRIM72 has a superior diagnostic value (the area under the curve (AUC) = 0.829) than the traditional tumor biomarkers, carcinoembryonic antigen (CEA) (AUC = 0.707) and carbohydrate antigen 19-9 (CA199) (AUC = 0.750), and the combination of TRIM72 with CEA and CA199 showed the best diagnostic value for colon cancer (AUC = 0.928).
|
29806630 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined TC, HDL, CEA and CA19-9 as a diagnostic marker for colon cancer had the highest positive predictive rate in comparison with individual, two or three of the parameters.
|
30458796 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate whether patients with elevated preoperative CEA that normalizes after colon cancer resection have a higher risk of recurrence than patients with normal preoperative CEA.
|
29270608 |
2018 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to analyze changes in the autonomic activity of colon cancer patients using heart rate variability (HRV) and blood pressure variability (BPV) measures, and to verify if HRV and BPV parameters correlate with hemodynamic indices in this group and the plasma levels of CEA.
|
29953262 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, both piRNAs exhibited satisfactory diagnostic performance also in patients with stage I disease and enabled detection of colon cancer with higher sensitivity than currently used biomarkers CEA and CA19-9.
|
29976566 |
2018 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Positive carcinoembryonic antigen (CEA) messenger RNA (mRNA) in peritoneal lavage is associated with poor prognosis in patients with colon cancer.
|
28291565 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biomarkers such as carcinoembryonic antigen (CEA) show low sensitivity (~ 40%), and thus the demand for novel biomarkers for CC diagnosis is increasing.
|
30382917 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
ChIP-sequencing revealed that Lv1 overexpression in IRF1-treated cells induces transcriptional silencing across many genes, including <i>DCC</i> (<u>d</u>eleted in <u>c</u>olorectal <u>c</u>arcinoma), associated with CEACAM5 in colon cancer.
|
29720400 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical value of a diagnostic score for colon cancer based on serum CEA, CA19-9, cytokeratin-1 and mucin-1.
|
29734875 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
A retrospective review of patients in Auckland with a new diagnosis of colon cancer in 2001 or 2005 was performed and CEA values were collected.
|
26245738 |
2017 |